ZA9807839B - Combination therapy. - Google Patents

Combination therapy.

Info

Publication number
ZA9807839B
ZA9807839B ZA9807839A ZA9807839A ZA9807839B ZA 9807839 B ZA9807839 B ZA 9807839B ZA 9807839 A ZA9807839 A ZA 9807839A ZA 9807839 A ZA9807839 A ZA 9807839A ZA 9807839 B ZA9807839 B ZA 9807839B
Authority
ZA
South Africa
Prior art keywords
combination therapy
therapy
combination
Prior art date
Application number
ZA9807839A
Inventor
Robert Andrew Donald Scott
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US5727697P priority Critical
Application filed by Pfizer filed Critical Pfizer
Publication of ZA9807839B publication Critical patent/ZA9807839B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
ZA9807839A 1997-08-29 1998-08-28 Combination therapy. ZA9807839B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US5727697P true 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
ZA9807839B true ZA9807839B (en) 2000-02-28

Family

ID=22009602

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9807839A ZA9807839B (en) 1997-08-29 1998-08-28 Combination therapy.

Country Status (41)

Country Link
US (2) US20020099046A1 (en)
EP (1) EP1009400B1 (en)
JP (2) JP2001514223A (en)
KR (3) KR20030015394A (en)
CN (3) CN1473566A (en)
AP (1) AP1191A (en)
AR (1) AR016399A1 (en)
AT (1) AT285767T (en)
AU (1) AU740424B2 (en)
BG (1) BG64724B1 (en)
BR (1) BR9811556A (en)
CA (1) CA2296723A1 (en)
CO (1) CO4970724A1 (en)
DE (1) DE69828413T2 (en)
DZ (1) DZ2595A1 (en)
EA (1) EA200000012A1 (en)
EG (1) EG24678A (en)
ES (1) ES2234134T3 (en)
GT (1) GT199800126A (en)
HR (1) HRP980474A2 (en)
HU (1) HU0004318A3 (en)
ID (1) ID24118A (en)
IL (2) IL133962D0 (en)
IS (1) IS5341A (en)
MA (1) MA26536A1 (en)
MY (1) MY121008A (en)
NO (1) NO323987B1 (en)
NZ (2) NZ502280A (en)
OA (1) OA11291A (en)
PA (1) PA8457901A1 (en)
PE (1) PE107099A1 (en)
PL (1) PL339091A1 (en)
PT (1) PT1009400E (en)
SA (1) SA973B1 (en)
SK (1) SK1432000A3 (en)
TN (1) TNSN98155A1 (en)
TR (1) TR200000563T2 (en)
UY (1) UY25155A1 (en)
WO (1) WO1999011260A1 (en)
YU (1) YU2000A (en)
ZA (1) ZA9807839B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GT199800127A (en) * 1997-08-29 2000-02-01 therapeutic combinations.
WO1999047138A1 (en) * 1998-03-17 1999-09-23 Warner-Lambert Company Statin-matrix metalloproteinase inhibitor combinations
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
DE19944803A1 (en) * 1999-09-20 2001-03-29 Bayer Ag Combination of dihydropyridine compounds, and HMG-CoA reductase inhibitors and their use in medicaments
AT309807T (en) 1999-09-24 2005-12-15 Vasogen Ireland Ltd Composition for the treatment of atherosclerosis, which contains a statin and ex vivo treated blood
FR2803525B1 (en) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Transduction inhibitor of heterotrimeric G protein signals associated with a antihypertensive agent in the treatment of high blood pressure
AR030414A1 (en) * 2000-04-03 2003-08-20 Astrazeneca Ab pharmaceutical combination comprising a beta blocker and an inhibitor of HMG-CoA reductase, pharmaceutical formulation, transportable equipment parts, this combination and use of this formulation for preparing medicaments
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (en) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
PT1313714E (en) 2000-07-19 2008-11-03 Novartis Ag Valsartan salts
AU8441301A (en) * 2000-08-30 2002-03-13 Sankyo Co Medicinal compositions for preventing or treating heart failure
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
EP1406660B1 (en) * 2001-07-19 2007-06-06 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
PE03242003A1 (en) * 2001-07-31 2003-04-03 Warner Lambert Co pharmaceutical compositions of amlodipine and atorvastatin
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2004000353A1 (en) * 2002-06-20 2003-12-31 The Governors Of The University Of Alberta Dichloroacetate in combination with cardioprotective or hemodynamic drugs
NZ537161A (en) * 2002-06-27 2007-09-28 Sb Pharmco Inc Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
US20050261355A1 (en) * 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
WO2004035051A1 (en) * 2002-10-16 2004-04-29 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005051383A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
ES2662903T3 (en) * 2003-11-25 2018-04-10 Smithkline Beecham (Cork) Limited carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and methods of treatment or administration
EP1734958A1 (en) * 2004-04-06 2006-12-27 Merck & Co., Inc. Methods for the treatment of hypertension
AU2005249794A1 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
CN104958270A (en) * 2004-08-25 2015-10-07 伊森舍丽斯有限公司 Pharmaceutical formulations of potassium ATP channel openers and uses thereof
CN100540003C (en) 2005-02-03 2009-09-16 北京华安佛医药研究中心有限公司 Medicinal composition containing amlodipine and terazosine
EP1848425B1 (en) * 2005-02-17 2011-08-17 CHIESI FARMACEUTICI S.p.A. Therapeutic combinations of manidi pine and simvastatin
JP5330825B2 (en) * 2006-03-29 2013-10-30 興和株式会社 Triglyceride lowering agents and hyperinsulinemia improving agent
AU2007314795B2 (en) * 2006-10-30 2012-02-16 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
EP2281557A4 (en) 2008-04-29 2011-08-31 Hanall Biopharma Co Ltd Pharmaceutical formulation containing angiotensin-ii receptor blocker
CZ301299B6 (en) * 2008-11-24 2010-01-06 Zentiva, A.S. Solid pharmaceutical composition with atorvastatin and telmisartan active ingredients
UA102721C2 (en) * 2009-01-23 2013-08-12 Ханми Сайенс Ко., Лтд. Solid pharmaceutical composition comprising amlodipine and losartan and a process for the preparation thereof
SI23149A (en) * 2009-09-21 2011-03-31 Silverstone Pharma New benzatin salts of ace inhibitors, procedure for their preparationand their application for treatment of cardiovascular diseases
RU2481124C1 (en) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Pharmaceutical combination of atorvastatin and nicergolin for preventing or treating cerebrovascular disease
CN102671198A (en) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 Compound medicine for reducing blood pressure and blood fat and preparation method thereof
KR20140028971A (en) * 2012-08-31 2014-03-10 한미약품 주식회사 Bilayered tablet composite formulation of atorvastatin, irbesartan and magnesium carbonate
WO2014142521A1 (en) * 2013-03-12 2014-09-18 주식회사 엘지생명과학 Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
CN104173420A (en) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 Acute renal failure treatment medicine
FR3040303A1 (en) * 2015-08-27 2017-03-03 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger A pharmaceutical composition comprising an inhibitor of HMG-CoA reductase and an inhibitor eca
CN105232555A (en) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 Telmisartan and rosuvastatin compound preparation and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (en) * 1989-07-21 1995-08-25 Warner Lambert Co Method pharmaceutically usable / R- (R *, R *) / - 2- (4-fluorophenyl) - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - / (phenylamino) carbonyl / -1 pyrrole-1-heptanoic acid and pharmaceutically acceptable salts thereof
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
NZ512484A (en) * 1995-11-02 2003-02-28 Warner Lambert Co Regulating lipid concentration in mammals by administering an acyl-CoA cholesterol O-acyltransferase (ACAT) inhibitor and an HMG-CoA reductase inhibitor

Also Published As

Publication number Publication date
EG24678A (en) 2010-04-27
HU0004318A3 (en) 2002-10-28
HRP980474A2 (en) 1999-06-30
IL133962A (en) 2006-07-05
KR20030015394A (en) 2003-02-20
PA8457901A1 (en) 2000-05-24
HU0004318A2 (en) 2001-05-28
AR016399A1 (en) 2001-07-04
EP1009400A1 (en) 2000-06-21
YU2000A (en) 2002-12-10
US20030199492A1 (en) 2003-10-23
NZ530630A (en) 2005-05-27
MA26536A1 (en) 2004-12-20
DZ2595A1 (en) 2003-02-22
JP2005041875A (en) 2005-02-17
WO1999011260A1 (en) 1999-03-11
NO20000996D0 (en) 2000-02-28
SK1432000A3 (en) 2000-12-11
CA2296723A1 (en) 1999-03-11
PE107099A1 (en) 1999-11-06
SA973B1 (en) 2006-07-04
AP1191A (en) 2003-07-19
NZ502280A (en) 2002-11-26
AU8458998A (en) 1999-03-22
BG104075A (en) 2000-09-29
IL133962D0 (en) 2001-04-30
PL339091A1 (en) 2000-12-04
JP2001514223A (en) 2001-09-11
EP1009400B1 (en) 2004-12-29
AP9801332A0 (en) 1998-09-30
NO323987B1 (en) 2007-07-30
BG64724B1 (en) 2006-01-31
PT1009400E (en) 2005-02-28
CO4970724A1 (en) 2000-11-07
AT285767T (en) 2005-01-15
EA200000012A1 (en) 2000-08-28
DE69828413D1 (en) 2005-02-03
DE69828413T2 (en) 2005-12-08
OA11291A (en) 2003-08-25
KR20010022477A (en) 2001-03-15
MY121008A (en) 2005-12-30
KR20040106591A (en) 2004-12-17
CN1268053A (en) 2000-09-27
CN1473566A (en) 2004-02-11
NO20000996L (en) 2000-04-27
TR200000563T2 (en) 2000-07-21
BR9811556A (en) 2000-08-22
GT199800126A (en) 2000-01-29
ES2234134T3 (en) 2005-06-16
TNSN98155A1 (en) 2005-03-15
AU740424B2 (en) 2001-11-01
UY25155A1 (en) 2000-12-29
IS5341A (en) 2000-01-14
ID24118A (en) 2000-07-06
CN1473567A (en) 2004-02-11
US20020099046A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
DE69826273D1 (en) Knochentransplantat-composite und -spacern
DE69817801D1 (en) Arylsulfonylhydroxamsäurederivate
DE69800640D1 (en) Pegylationsverfahren
DE69807872D1 (en) Thermoplastisches polyetherurethan
DE69817191D1 (en) Roboter-mäher
DE69821950D1 (en) N-aroylphenylalaninderivate
DE69837675D1 (en) Pyrazolderivate
DE69709184D1 (en) Knöchel-fuss orthese
DE69804946D1 (en) Opthalmische formmasse
DE69831868D1 (en) Antithrombosemittel
DE69808438D1 (en) Hüftprothese
DE69827612D1 (en) Meatuspfropf
DE69809754D1 (en) Substituierte 6-phenylphenanthridine
DE69812937D1 (en) Direkt-digitale holographie, holographische interferometrie und holovision
DE69829667D1 (en) Hydrocyanierungsverfahren
DE69816992D1 (en) Benzimidazolderivate
DE69827940D1 (en) Thiarylsulfonamid-hydroxamsäurederivate
DE69837702D1 (en) Lastsensor
DE69835201D1 (en) Neoglycoproteine
DE69840963D1 (en) Thermale therapievorrichtung
DE69813225D1 (en) Blockcopolymere
DE69837398D1 (en) Festphasenextrationsplatte
DE69838100D1 (en) Gefässprothese
DE59804066D1 (en) Triazolinthion-phosphorsäure-derivate
DE69830051D1 (en) Endotrachealtubus